Few sex differences in the use of drugs for secondary prevention after stroke: A nationwide observational study

Pharmacoepidemiology and Drug Safety

Volumn 21, Issue 9, 2012, Pages 911-919

  Sjölander, Maria ^a   Eriksson, Marie ^a   Glader, Eva Lotta ^a  

^a UMEÅ UNIVERSITY   (Sweden)

Author keywords

Drug therapy; Ischemic stroke; Persistence; Secondary prevention; Sex differences

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; WARFARIN;

AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; BRAIN ISCHEMIA; CONTROLLED STUDY; DRUG UTILIZATION; FEMALE; HOSPITAL DISCHARGE; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PRESCRIPTION; PRIORITY JOURNAL; SECONDARY PREVENTION; SEX DIFFERENCE;

AGED; ANTIHYPERTENSIVE AGENTS; DATABASES, FACTUAL; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MEDICATION ADHERENCE; PHYSICIAN'S PRACTICE PATTERNS; PLATELET AGGREGATION INHIBITORS; REGISTRIES; SECONDARY PREVENTION; SEX FACTORS; STROKE; SWEDEN; WARFARIN;

EID: 84865864219     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.2268     Document Type: Article

References (24)

1. Stegmayr B, Asplund K. Improved survival after stroke but unchanged risk of incidence. Lakartidningen 2003; 100: 3492-3498.
2. Ghatnekar O, Persson U, Glader E-L, et al. Cost of stroke in Sweden: An incidence estimate. Int J Technol Assess Health Care 2004; 20: 375-380.
3. Socialstyrelsen. Nationella riktlinjer för strokesjukvård 2009-stöd för styrning och ledning. 2009.
4. The European Stroke Organization Executive Committee, The European Stroke Organisation Writing Committee. Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. 2008.
5. Turtzo LC, McCullough LD. Sex differences in stroke. Cerebrovasc Dis 2008; 26: 462-474.
6. Gargano JW, Wehner S, Reeves M. Sex differences in acute stroke care in a statewide stroke registry. Stroke 2008; 39: 24-29.
7. Arrich J, Mullner M, Lalouschek W, et al. Influence of socioeconomic status and gender on stroke treatment and diagnostics. Stroke 2008; 39: 2066-2072.
8. Smith DB, Murphy P, Santos P, et al. Gender differences in the Colorado stroke registry. Stroke 2009; 40: 1078-1081.
9. Raine R, Wong W, Ambler G, et al. Sociodemographic variations in the contribution of secondary drug prevention to stroke survival at middle and older ages: Cohort study. BMJ 2009; 338: b1279.
10. Ekedahl A, Månsson N. Unclaimed prescriptions after automated prescription transmittals to pharmacies. Pharm World Sci 2004; 26: 26-31.
11. Hagstrom B, Mattsson B, Rost I-M, et al. What happened to the prescriptions?: A single, short, standardized telephone call may increase compliance. Fam Pract 2004; 21: 46-50.
12. Jackevicius CA, Li P, Tu JV. Prevalence, predictors, and outcomes of primary nonadherence after acute myocardial infarction. Circulation 2008; 117: 1028-1036.
13. De Schryver E, van Gijn J, Kappelle L, et al. Non-adherence to aspirin or oral anticoagulants in secondary prevention after ischaemic stroke. J Neurol 2005; 252: 1316-1321.
14. Sappok T, Faulstich A, Stuckert E, et al. Compliance with secondary prevention of ischemic stroke: A prospective evaluation. Stroke 2001; 32: 1884-1889.
15. Asplund K, Hulter Åsberg K, Norrving B, et al. Riks-Stroke-a Swedish national quality register for stroke care. Cerebrovasc Dis 2003; 15: 5-7.
16. Wettermark B, Hammar N, Fored CM, et al. The new Swedish Prescribed Drug Register-opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiol Drug Saf 2007; 16: 726-735.
17. Palnum KH, Mehnert F, Andersen G, et al. Medical prophylaxis following hospitalization for ischemic stroke: Age- and sex-related differences and relation to mortality. Cerebrovasc Dis 2010; 30: 556-566.
18. Eriksson M, Glader E-L, Norrving B, et al. Sex differences in stroke care and outcome in the Swedish national quality register for stroke care. Stroke 2009; 40: 909-914.
19. Glader E-L, Stegmayr B, Norrving B, et al. Sex differences in management and outcome after stroke: A Swedish national perspective. Stroke 2003; 34: 1970-1975.
20. Lalouschek W, Lang W, Greisenegger S, et al. Determination of lipid profiles and use of statins in patients with ischemic stroke or transient ischemic attack. Stroke 2003; 34: 105-110.
21. Burke TA, Sturkenboom MC, Lu S-E, et al. Discontinuation of antihypertensive drugs among newly diagnosed hypertensive patients in UK general practice. J Hypertens 2006; 24: 1193-1200.
22. Mazzaglia G, Ambrosioni E, Alacqua M, et al. Adherence to antihypertensive medications and cardiovascular morbidity among newly diagnosed hypertensive patients. Circulation 2009; 120: 1598-1605.
23. Riks-Stroke. Riks-Stroke årsrapport 2009. 2010. http://www.riks-stroke.org/content/analyser/Rapport09.pdf (accessed 3 January 2011).
24. Goldstein LB, Amarenco P, LaMonte M, et al. Relative effects of statin therapy on stroke and cardiovascular events in men and women: Secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) study. Stroke 2008; 39: 2444-2448.